<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123368</url>
  </required_header>
  <id_info>
    <org_study_id>CMM/ART</org_study_id>
    <secondary_id>2009-017624-72</secondary_id>
    <nct_id>NCT02123368</nct_id>
  </id_info>
  <brief_title>Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells</brief_title>
  <official_title>Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)&#xD;
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients&#xD;
      with knee osteoarthritis.&#xD;
&#xD;
      Patients and methods&#xD;
&#xD;
      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10&#xD;
      patients for each group. The investigators compare the intraarticular injection of hialuronic&#xD;
      acid against the administration of two different doses of mesenchymal stem cells with&#xD;
      hialuronic acid according to the following scheme:&#xD;
&#xD;
        1. Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose.&#xD;
&#xD;
        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous&#xD;
           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small&#xD;
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an&#xD;
           intraarticular injection Hiaurónico Acid ( Hyalone®).&#xD;
&#xD;
        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous&#xD;
           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small&#xD;
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an&#xD;
           intraarticular injection Hiaurónico Acid (Hyalone®).&#xD;
&#xD;
      The primary endpoint is safety and feasibility. The investigators registered the occurrence&#xD;
      of complications and / or adverse effects during the study.&#xD;
&#xD;
      In addition the investigators assess the response to intra-articular infusion of CMM&#xD;
      analyzing the following parameters:&#xD;
&#xD;
        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since&#xD;
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.&#xD;
&#xD;
        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.&#xD;
&#xD;
        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the&#xD;
           number location of the lesions , cartilage thickness , signal intensity , subchondral&#xD;
           bone alteration , volume and WORMS and dGEMRIC protocols.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)&#xD;
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) in patients&#xD;
      with knee osteoarthritis.&#xD;
&#xD;
      Patients and methods&#xD;
&#xD;
      Clinical trial phase I- II, randomized , multicenter , with three treatment arms and 10&#xD;
      patients for each group. The investigators compare the intraarticular injection of hialuronic&#xD;
      acid against the administration of two different doses of mesenchymal stem cells with&#xD;
      hialuronic acid according to the following scheme:&#xD;
&#xD;
        1. Group A: intra-articular injection of hyaluronic acid (Hyalone®). Single dose.&#xD;
&#xD;
        2. Group B: Low Dosage of MSCs . Intra-articular injection of 10 million autologous&#xD;
           mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile small&#xD;
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an&#xD;
           intraarticular injection Hiaurónico Acid ( Hyalone®).&#xD;
&#xD;
        3. Group C : High dose of MSCs. Intra-articular injection of 100 million autologous&#xD;
           mesenchymal progenitor stem cells cultured ex - vivo ( cell suspension sterile small&#xD;
           volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by an&#xD;
           intraarticular injection Hiaurónico Acid (Hyalone®).&#xD;
&#xD;
      The autologous mesenchymal stem cells are obtained from the iliac crest and cultured ex vivo&#xD;
      under local anesthesia and sedation.&#xD;
&#xD;
      The primary endpoint is safety and feasibility. The investigators registered the occurrence&#xD;
      of complications and / or adverse effects during the study.&#xD;
&#xD;
      In addition the investigators assess the response to intra-articular infusion of CMM&#xD;
      analyzing the following parameters:&#xD;
&#xD;
        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since&#xD;
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.&#xD;
&#xD;
        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.&#xD;
&#xD;
        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the&#xD;
           number location of the lesions , cartilage thickness , signal intensity , subchondral&#xD;
           bone alteration , volume and WORMS and dGEMRIC protocols.&#xD;
&#xD;
      All patients met the following inclusion and exclusion criteria:&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Males and females between 50 and 80 year old.&#xD;
&#xD;
        -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American&#xD;
           College of Rheumatology).&#xD;
&#xD;
        -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).&#xD;
&#xD;
        -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.&#xD;
&#xD;
        -  Body mass index between 20 and 35 kg/m2.&#xD;
&#xD;
        -  Ability to follow during the study period.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.&#xD;
&#xD;
        -  Previous diagnosis of polyarticular disease.&#xD;
&#xD;
        -  Severe mechanical deformation.&#xD;
&#xD;
        -  Arthroscopy during the previous 6 months.&#xD;
&#xD;
        -  Intraarticular infiltration of hyaluronic acid in the last 6 months.&#xD;
&#xD;
        -  Systemic autoimmune rheumatic disease.&#xD;
&#xD;
        -  Poorly controlled diabetes mellitus.&#xD;
&#xD;
        -  Blood dyscrasias.&#xD;
&#xD;
        -  Immunosuppressive or anticoagulant treatments.&#xD;
&#xD;
        -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.&#xD;
&#xD;
        -  NSAID therapy within 15 days prior to inclusion in the study.&#xD;
&#xD;
        -  Patients with a history of allergy to penicillin or streptomycin.&#xD;
&#xD;
        -  Allergy to hyaluronic acid or poultry proteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Visual analogue scale (VAS)</measure>
    <time_frame>prior to the initial dose on day 1</time_frame>
    <description>Baseline Visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline value of knee injury and osteoarthritis outcome score (Koos).</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline SF-36 value</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline euroquol 5D value</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Pretreatment euroquol 5D value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lequesne index</measure>
    <time_frame>Prior to the intervention on day 1</time_frame>
    <description>Prior to the intervention on day 1 Lequesne index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline femorotibial distance</measure>
    <time_frame>Prior to the intervention</time_frame>
    <description>Prior to the intervention femoritibial distance on rosenberg x-ray view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Follow up</time_frame>
    <description>During the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at on month</measure>
    <time_frame>1 month</time_frame>
    <description>Visual analogue scale (VAS) at on month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue scale (VAS) at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale (VAS) at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual analogue scale (VAS) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</measure>
    <time_frame>3 Months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month</measure>
    <time_frame>3 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36 value at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>SF 36 value at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>SF 36 value at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF 36 value at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>SF 36 value at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 1 month</measure>
    <time_frame>1 MOnth</time_frame>
    <description>Euroquol 5D value at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Euroquol 5D value at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Euroquol 5D value at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Euroquol 5D value at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Euroquol 5D value at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Lequesne index at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Lequesne index at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Lequesne index at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne index at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Lequesne index at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Femorotibial distance at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Femorotibial distance at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Femorotibial distance at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Femorotibial distance at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline MRI WORMS protocol</measure>
    <time_frame>Prior to the intervention</time_frame>
    <description>Prior to the intervention MRI WORMS protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI WORMS protocol score at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>MRI WORMS protocol score at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRI WORMS protocol score at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>MRI WORMS protocol score at 12 months</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hialuronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid</intervention_name>
    <description>Single intraarticular injection of Hyaluronic acid (Hyal One)</description>
    <arm_group_label>Hialuronic acid</arm_group_label>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
    <other_name>HyalOne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>10 million of Bone marrow mesenchimal stem cells</description>
    <arm_group_label>Hyaluronic acid and MSC 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>100 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>100 million of Bone marrow mesenchimal stem cells</description>
    <arm_group_label>Hyaluronic acid AND MSC 100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 50 and 80 year old.&#xD;
&#xD;
          -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American&#xD;
             College of Rheumatology).&#xD;
&#xD;
          -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS).&#xD;
&#xD;
          -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2.&#xD;
&#xD;
          -  Body mass index between 20 and 35 kg/m2.&#xD;
&#xD;
          -  Ability to follow during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees.&#xD;
&#xD;
          -  Previous diagnosis of polyarticular disease.&#xD;
&#xD;
          -  Severe mechanical deformation.&#xD;
&#xD;
          -  Arthroscopy during the previous 6 months.&#xD;
&#xD;
          -  Intraarticular infiltration of hyaluronic acid in the last 6 months.&#xD;
&#xD;
          -  Systemic autoimmune rheumatic disease.&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus.&#xD;
&#xD;
          -  Blood dyscrasias.&#xD;
&#xD;
          -  Immunosuppressive or anticoagulant treatments.&#xD;
&#xD;
          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study.&#xD;
&#xD;
          -  NSAID therapy within 15 days prior to inclusion in the study.&#xD;
&#xD;
          -  Patients with a history of allergy to penicillin or streptomycin.&#xD;
&#xD;
          -  Allergy to hyaluronic acid or poultry proteins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Lamo-Espinosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Blanco, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Traumatology department. Complejo Hospitalario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla y León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic and traumatology department. Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla</url>
    <description>University clinic of navarre trial information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Mesenchimal stem cell</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

